{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:12:02Z","timestamp":1785787922620,"version":"3.56.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20250980"],"award-info":[{"award-number":["20250980"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>\n                    Bleeding peptic ulcers remain a major cause of non-variceal upper gastrointestinal hemorrhage, and optimizing post-endoscopic pharmacologic therapy is essential to reducing early rebleeding and improving clinical outcomes. This study evaluated the therapeutic effectiveness of high-dose versus low-dose omeprazole following endoscopic hemostasis. This retrospective observational study included patients with endoscopically confirmed bleeding peptic ulcers treated between August 2022 and August 2025. Patients received either high-dose omeprazole (80-mg intravenous loading dose followed by continuous infusion at 4\u2009mg\/h) or low-dose omeprazole (40\u2009mg intravenously once daily) after endoscopic hemostasis. Hemoglobin, hematocrit, rebleeding rates, clinical recovery parameters, and adverse events were collected. Participants were followed for 30 days to evaluate delayed rebleeding. Continuous variables were analyzed using independent-samples\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    tests, and categorical variables using chi-square tests. A total of 119 patients were included (high-dose: n\u2005=\u200558; low-dose: n\u2005=\u200561). High-dose omeprazole significantly reduced rebleeding at 72 hours (6.9% vs 21.3%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.025) and 30 days (10.3% vs 29.5%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009). Greater increases in hemoglobin and hematocrit, lower transfusion volume, faster cessation of bleeding, earlier hemodynamic stabilization, and shorter hospitalization were also observed (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Adverse event rates were comparable between groups. High-dose omeprazole combined with endoscopic hemostasis enhances hemostatic stability, accelerates clinical recovery, and reduces short-term rebleeding without increasing treatment-related adverse events.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047681","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:00:21Z","timestamp":1772240421000},"page":"e47681","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of omeprazole combined with endoscopic hemostasis in the treatment of patients with bleeding peptic ulcers"],"prefix":"10.1097","volume":"105","author":[{"given":"Xiaozhu","family":"Fan","sequence":"first","affiliation":[{"name":"Emergency and Critical Care Center, Hebei Engineering University Affiliated Hospital, Handan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Hebei Engineering University Affiliated Hospital, Handan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Lian","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Hebei Engineering University Affiliated Hospital, Handan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Miao","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Handan 285 Hospital of China Rongtong Medical and Health Group, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Song","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Handan 285 Hospital of China Rongtong Medical and Health Group, Handan, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4151-5633","authenticated-orcid":false,"given":"Shumin","family":"Niu","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Hebei Engineering University Affiliated Hospital, Handan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1053\/j.gastro.2024.03.036","article-title":"Comparison of vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial.","volume":"167","author":"Geeratragool","year":"2024","journal-title":"Gastroenterology"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.62347\/CJAZ6726","article-title":"Risk factors and prediction model for rebleeding in grade IIb peptic ulcer patients after endoscopy.","volume":"17","author":"Wang","year":"2025","journal-title":"Am J Transl Res"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2125.2008.03359.x","article-title":"Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection.","volume":"67","author":"Tsai","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1572-0241.2006.00399.x","article-title":"Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial.","volume":"101","author":"Lin","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2036.2009.04049.x","article-title":"Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study.","volume":"30","author":"Tseng","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"1507812","DOI":"10.3389\/fphar.2025.1507812","article-title":"Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors.","volume":"16","author":"Wo\u0142owiec","year":"2025","journal-title":"Front Pharmacol"},{"key":"R7-20260413","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/ncpgasthep0578","article-title":"High-dose or low-dose omeprazole after endoscopic hemostasis in patients with peptic ulcer bleeding?","volume":"3","author":"Lau","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40780-024-00398-y","article-title":"The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study.","volume":"10","author":"Ide","year":"2024","journal-title":"J Pharm Health Care Sci"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"e000202","DOI":"10.1136\/bmjmed-2022-000202","article-title":"Update on the management of upper gastrointestinal bleeding.","volume":"1","author":"Orpen-Palmer","year":"2022","journal-title":"BMJ Med"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ajg.2016.582","article-title":"Reassessment of rebleeding risk of forrest IB (Oozing) peptic ulcer bleeding in a large international randomized trial.","volume":"112","author":"Jensen","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/1751-2980.12447","article-title":"Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding.","volume":"18","author":"Lau","year":"2017","journal-title":"J Dig Dis"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"goad011","DOI":"10.1093\/gastro\/goad011","article-title":"An update on the management of non-variceal upper gastrointestinal bleeding.","volume":"11","author":"Alali","year":"2023","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1751-2980.12393","article-title":"Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: a randomized prospective study.","volume":"17","author":"Chwiesko","year":"2016","journal-title":"J Dig Dis"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/s-0042-107590","article-title":"High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial.","volume":"48","author":"Chiu","year":"2016","journal-title":"Endoscopy"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12876-024-03261-4","article-title":"Proton pump inhibitor therapy after transcatheter angiography in refractory nonvariceal acute upper gastrointestinal bleeding patients: a cohort study.","volume":"24","author":"Xiao","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/medicina61091569","article-title":"Proton pump inhibitors (PPIs)-an evidence-based review of indications, efficacy, harms, and deprescribing.","volume":"61","author":"Andrawes","year":"2025","journal-title":"Medicina (Kaunas)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:17:24Z","timestamp":1785784644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047681","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}